Evidence map›Paper›PMID 25366685›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert and 6 more

3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 890 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
890citing papers in PubMed, 5 pooled it
71.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02869802 recruitingnot on this mapstarted 2016, after this paper: background citation

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

TypeobservationalSponsorBritish Columbia Cancer AgencyRan2016 to 2027Enrolled190ConditionsCancer, Pancreatic CancerArmsTumour Biopsy, Serial Collection of Plasma and Serum Samples
NCT03587129 phase2terminatednot on this mapstarted 2018, after this paper: background citation

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

TypeinterventionalSponsorFirst Affiliated Hospital of Harbin Medical UniversityRan2018 to 2020Enrolled1ConditionsOvarian CancerArmsApatinib
NCT04716686 phase2recruitingnot on this mapstarted 2021, after this paper: background citation

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma: A Multi-center, Open-label, Prospective Clinical Study

TypeinterventionalSponsorShandong UniversityRan2021 to 2026Enrolled83ConditionsEndometrial Carcinoma, Serous CarcinomaArmsNiraparib
3 · Its place in the literature

Who cites it

890 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,667 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. BCLXSignal transduction and targeted therapy · 2026
    Article
  20. Article

830 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Bella KaufmanBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Ronnie Shapira-FrommerBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Rita K SchmutzlerBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
M William AudehBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Michael FriedlanderBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Judith BalmañaBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Gillian MitchellBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Georgeta FriedBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Salomon M StemmerBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Ayala HubertBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Ora RosengartenBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Mariana SteinerBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Niklas LomanBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Karin BowenBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Anitra FieldingBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Susan M DomchekBella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Judith Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas Loman, Skånes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. susan.domchek@uphs.upenn.edu.
AstraZeneca (United Kingdom) · GBUniversity of Pennsylvania · US

Funding

UNIVERSITY OF PENNSYLVANIA CANCER GENETICS NETWORKU24CA078156 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DOMCHEK, SUSAN M. · 1998 to 2006
$3.4M
NCI NIH HHS U24 CA078156
6 · The paper itself

Abstract

purposeOlaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers. PATIENTS AND

methodsThis multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer. Eligibility included ovarian cancer resistant to prior platinum; breast cancer with ≥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy. Olaparib was administered at 400 mg twice per day. The primary efficacy end point was tumor response rate.

resultsA total of 298 patients received treatment and were evaluable. The tumor response rate was 26.2% (78 of 298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, pancreatic, and prostate cancers, respectively. Stable disease ≥ 8 weeks was observed in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, respectively. The most common adverse events (AEs) were fatigue, nausea, and vomiting. Grade ≥ 3 AEs were reported for 54% of patients; anemia was the most common (17%).

conclusionResponses to olaparib were observed across different tumor types associated with germline BRCA1/2 mutations. Olaparib warrants further investigation in confirmatory studies.

Indexed as

Germ-Line MutationAdultAgedAntineoplastic AgentsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsDisease-Free SurvivalDrug Administration ScheduleFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasmsOvarian NeoplasmsAntineoplastic AgentsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanolaparibPhthalazinesPiperazines

Identifiers

PMID25366685
PMCPMC6057749
OpenAlexW2111437716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.